| Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib. |
|
Eun Kyu Oh, Dong Hyun Jo, Mee Kum Kim, Won Ryang Wee |
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. kmk9@snu.ac.kr
2Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute, Seoul, Korea. |
| 에를로티닙과 라파티닙을 사용한 환자에서 발생한 표층점상각막병증 |
|
오은규1,2⋅조동현1,2⋅김미금1,2⋅위원량1,2 |
|
Department of Ophthalmology, Seoul National University College of Medicine1, Seoul, Korea Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute2, Seoul, Korea |
|
|
| Abstract |
PURPOSE
To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. CASE SUMMARY: Case 1, who received erlotinib, showed trichomegaly without touching the cornea and diffuse punctate keratoepitheliopathy. Corneal epitheliopathy and the corresponding symptoms resolved after discontinuation of the drug then recurred with reapplication. Case 2 presented diffuse corneal punctate epithelial erosions that developed without any cilia involvement after the patient was administered lapatinib. The visual acuity of both patients was not severely diminished and keratoepitheliopathy was mostly resolved with the treatment of preservative-free artificial tears and autologous serum eye drops. CONCLUSIONS: Erlotinib and lapatinib are both likely to cause visually tolerable corneal punctate keratoepitheliopathy which can be resolved with appropriate topical treatment. |
| Key Words:
Cancer treatment;Corneal erosion;Epidermal growth factor |
|
PDF Links
Full text via DOI
Download Citation
